- Home
- PHGE vs KXIN Comparison
PHGE vs KXIN Comparison
Compare PHGE & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- KXIN
- Stock Information
- Founded
- PHGE 2015
- KXIN 2015
- Country
- PHGE Israel
- KXIN China
- Employees
- PHGE N/A
- KXIN N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- KXIN Retail-Auto Dealers and Gas Stations
- Sector
- PHGE Health Care
- KXIN Consumer Discretionary
- Exchange
- PHGE Nasdaq
- KXIN Nasdaq
- Market Cap
- PHGE 11.0M
- KXIN 10.4M
- IPO Year
- PHGE N/A
- KXIN N/A
- Fundamental
- Price
- PHGE $0.39
- KXIN $0.91
- Analyst Decision
- PHGE Strong Buy
- KXIN
- Analyst Count
- PHGE 1
- KXIN 0
- Target Price
- PHGE $15.00
- KXIN N/A
- AVG Volume (30 Days)
- PHGE 3.0M
- KXIN 118.9K
- Earning Date
- PHGE 08-13-2025
- KXIN 01-01-0001
- Dividend Yield
- PHGE N/A
- KXIN N/A
- EPS Growth
- PHGE N/A
- KXIN N/A
- EPS
- PHGE N/A
- KXIN N/A
- Revenue
- PHGE N/A
- KXIN N/A
- Revenue This Year
- PHGE N/A
- KXIN N/A
- Revenue Next Year
- PHGE N/A
- KXIN N/A
- P/E Ratio
- PHGE N/A
- KXIN N/A
- Revenue Growth
- PHGE N/A
- KXIN N/A
- 52 Week Low
- PHGE $0.34
- KXIN $0.64
- 52 Week High
- PHGE $3.48
- KXIN $29.54
- Technical
- Relative Strength Index (RSI)
- PHGE 37.11
- KXIN 51.27
- Support Level
- PHGE $0.38
- KXIN $0.86
- Resistance Level
- PHGE $0.77
- KXIN $0.99
- Average True Range (ATR)
- PHGE 0.06
- KXIN 0.08
- MACD
- PHGE -0.00
- KXIN 0.00
- Stochastic Oscillator
- PHGE 6.52
- KXIN 36.31
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.